The leader in pharma sales, Pfizer is well known thanks to several household name drugs, including Lipitor, Advil, Celebrex, Zithromax and the ever-abundant "little blue pill," Viagra. As the company looks at the looming Lipitor patent cliff, CEO Ian Read has been searching for new methods to keep revenue high, other than new approved drugs. Recently, the company has been considering spinning off portions of the company to create smaller, more profitable arms, a polar opposite of former CEO Jeffrey Kindler's bulk-up strategy of years past. The company's past purchases and mergers have included King Pharmaceuticals, Warner-Lambert, SUGEN and a $68 billion purchase, Wyeth, in 2009.

Wyeth provided Pfizer with an influx of 17 new drugs and vaccines, including Enbrel, Effexor, Prevnar and Pristiq, and Pfizer declared the merger made them "one of the most diversified companies in the global health care industry." And the company continues to move forward as it focuses on hot areas, including Alzheimer's, oncology and vaccines.

The company's legal woes have caused headaches as well. Pfizer has paid over $340 million in settlements for its menopause treatment, Prempro and has 1,200 cases pending for the anti-smoking drug Chantix. Back in 2009, it paid $1.3 billion for illegal marketing fines for the painkiller Bextra, making it the largest fine in United States history.

Pfizer has stayed in the top two on FiercePharma's annual layoffs list for the past three years, thanks in part to the company's 2009 megamerger with Wyeth, and the pressure could be felt for another five years. The company also placed second in the Top 15 R&D Budgets, with $7.4 billion in 2009. But those numbers will continue to slip as Pfizer looks towards development deals instead of in-house research.



Latest Headlines

Latest Headlines

Biotech entrepreneurs grow a new CRO in China

Biotech entrepreneur John Oyler--who helped found Genta and Galanea--sat down with Chemistry World to discuss his three-year-old

Pfizer gets new cancer team to advance key drugs

With the clock ticking on its patent for Lipitor, Pfizer has turned to a group of new executives to

EU commissioner widens pharma probe

Europe's competition commissioner is casting a wide net in her pharma-market antitrust probe. After questioning some 100 companies--including Pfizer, GlaxoSmithKline, and

SPOTLIGHT: Pfizer to disclose grants, donations

Pfizer is pledging "greater transparency" in its dealings with medical, scientific, and patient organizations; its first step is disclosing all grants and charitable contributions for the first

Pfizer rumored to be eyeing MediGene buyout

Rumors are swirling that Pfizer is looking to take over the German biotech

Rumor Mill: Pfizer eyeing MediGene

Rumors are swirling that Pfizer is looking to take over the German biotech

Painkillers little help against dementia

Hopes that painkillers might help stave off Alzheimer's disease were dampened by a large new study. Pfizer's Celebrex and the over-the-counter Aleve didn't benefit thinking skills as researchers had

SPOTLIGHT: Ex-Exubera plant to shut down

Pfizer will shutter its sterile manufacturing plant in Terre Haute--where the now-defunct inhaled insulin product Exubera was made--by mid-2009, eliminating the facility's remaining 140 jobs. More

Silver lining to Big Pharma's cloud?

Some people see the Big Pharma glass as half-full instead of the alternative. In an investor's-eye look at the industry, Kiplinger ticks off the usual criticisms: patent expirations, tough generics

SPOTLIGHT: Feds tout Chantix in stop-smoking guidelines

The federal government's new stop-smoking guidelines recommend Chantix, the Pfizer drug that has been linked to depression and suicidal behavior, saying that the drug's effectiveness outweighs those